<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201861</url>
  </required_header>
  <id_info>
    <org_study_id>SHPD004</org_study_id>
    <nct_id>NCT03201861</nct_id>
  </id_info>
  <brief_title>Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women</brief_title>
  <official_title>Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based
      regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer
      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, patients will be randomly assigned in a 2:1 ratio to receive cisplatin-based
      adjuvant chemotherapy and to standard adjuvant chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Disease-Free Survival (DFS) Events</measure>
    <time_frame>up to 5 year follow up</time_frame>
    <description>DFS is defined as the time period between registration and first event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival (OS) Events</measure>
    <time_frame>up to 5 year follow up</time_frame>
    <description>OS is defined as the time period between registration and first event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v3.0.</measure>
    <time_frame>5 months during adjuvant therapy</time_frame>
    <description>Descriptive statistics for the treatment will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">762</enrollment>
  <condition>Tubular Breast Cancer</condition>
  <condition>Mucinous Breast Cancer</condition>
  <condition>Invasive Duct Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>paclitaxel and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epirubicin and cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel
Investigators will declare one of the following regimens:
Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.
Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel, Cisplatin</intervention_name>
    <description>weekly paclitaxel and cisplatin</description>
    <arm_group_label>paclitaxel and cisplatin</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC to docetaxel or paclitaxel</intervention_name>
    <description>Standard adjuvant chemotherapy recommended by guideline</description>
    <arm_group_label>epirubicin and cyclophosphamide</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥18 years and ≤70 years

          2. Have accepted surgical treatment, histologically confirmed early breast cancer, the
             pathological types of invasive carcinoma

          3. Not received treatment for breast cancer before operation

          4. Triple-negative breast cancer confirmed by pathology, or pathology confirmed as the HR
             positive breast cancer at the same time meet the following conditions: axillary lymph
             node positive breast cancer, tumor size≥2 cm and Ki - 67 &gt;20% or tumor size ≥2 cm and
             grade III or tumor size ≥2cm and aged &lt;35 years

          5. HER2 negative: immunohistochemistry HER2 (1 +) or HER2 (0), or fluorescence in situ
             hybridization (FISH): not amplified

          6. Performance status (PS) 0-1

          7. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L,
             Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine
             aminotransferase (ALT)≤1.5 upper normal limit , creatinine≤1.5 upper normal limit,
             bilirubin≤1.5 upper normal limit

          8. No obvious main organs dysfunction

        Exclusion Criteria:

          1. metastatic breast cancer

          2. Patient is pregnant or breast feeding

          3. Any evidence of sense or motor nerve disorders

          4. Bilateral Primary Breast Cancer (DCIS in one side not included)

          5. Patients with medical conditions taht indicate intolerant to adjuvant chemotherapy,
             including uncontrolled cardiovascular disease, severe infection

          6. Have received chemotherapy because of any malignancy other than breast cancer

          7. Known severe hypersensitivity to any drugs in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsong Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yueyao Du, M.D.</last_name>
    <phone>86-21-68385569</phone>
    <email>jessicayy8629@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Zhang, M.D.</last_name>
    <phone>86-21-68385516</phone>
    <email>doudou090227@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyao Du, M.D.</last_name>
      <phone>86-21-68385569</phone>
      <email>jessicayy8629@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jie Zhang, M.D.</last_name>
      <phone>86-21-68385516</phone>
      <email>doudou090227@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015 Jul 20;33(21):2353-60. doi: 10.1200/JCO.2015.60.9271. Epub 2015 Jun 15.</citation>
    <PMID>26077235</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

